Perfluorinated compounds in relation to birth weight in the Norwegian Mother and Child Cohort Study

American Journal of Epidemiology

Volumn 175, Issue 12, 2012, Pages 1209-1216

  Whitworth, Kristina W ^a   Haug, Line S ^b   Baird, Donna D ^a   Becher, Georg ^b   Hoppin, Jane A ^a   Skjaerven, Rolv ^b,c   Thomsen, Cathrine ^b   Eggesbo, Merete ^b   Travlos, Gregory ^a   Wilson, Ralph ^a   Cupul Uicab, Lea A ^a   Brantsaeter, Anne Lise ^b   Longnecker, Matthew P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Birth weight; MoBa; Norwegian Mother and Child cohort Study; Perfluorinated compounds; Perfluorooctane sulfonate; Perfluorooctanoic acid

Indexed keywords

PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

BIRTH RATE; CHILD HEALTH; CHILDBEARING; COHORT ANALYSIS; ORGANIC POLLUTANT; ORGANOFLUORINE; PREGNANCY;

ADULT; ARTICLE; BIRTH WEIGHT; BLOOD LEVEL; CELL COUNT; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GESTATION PERIOD; HUMAN; HUMAN CELL; LARGE FOR GESTATIONAL AGE; MAJOR CLINICAL STUDY; MATERNAL PLASMA; NORWAY; OUTCOME ASSESSMENT; PREMATURITY; SMALL FOR DATE INFANT;

ADULT; ALKANESULFONIC ACIDS; BIRTH WEIGHT; DIET SURVEYS; ENVIRONMENTAL POLLUTANTS; FEMALE; FETAL MACROSOMIA; FLUOROCARBONS; FOOD CONTAMINATION; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MATERNAL EXPOSURE; NORWAY; OCTANOIC ACIDS; ODDS RATIO; PREGNANCY; PREMATURE BIRTH; PROSPECTIVE STUDIES; SEAFOOD; SINGLE-BLIND METHOD;

NORWAY;

EID: 84862505545     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr459     Document Type: Article

References (46)

1. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect. 2010;118(8):1100-1108.
2. Bartell SM, Calafat AM, Lyu C, et al. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect. 2010;118(2):222-228.
3. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9):1298-1305. (Pubitemid 47471253)
4. Haug LS, Thomsen C, Brantsaeter AL, et al. Diet and particularly seafood are major sources of perfluorinated compounds in humans. Environ Int. 2010;36(7):772-778.
5. D'Hollander W, de Voogt P, De Coen W, et al. Perfluorinated substances in human food and other sources of human exposure. Rev Environ Contam Toxicol. 2010;208:179-215. (doi:10.1007/978-1-4419-6880-7-4).
6. Han X, Snow TA, Kemper RA, et al. Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem Res Toxicol. 2003;16(6):775-781. (Pubitemid 36736609)
7. Zhang X, Chen L, Fei XC, et al. Binding of PFOS to serum albumin and DNA: insight into the molecular toxicity of perfluorochemicals. BMC Mol Biol. 2009;10:16. (doi:10.1186/1471-2199-10-16).
8. Jones PD, Hu W, De Coen W, et al. Binding of perfluorinated fatty acids to serum proteins. Environ Toxicol Chem. 2003;22(11):2639-2649. (Pubitemid 37214748)
9. Apelberg BJ, Witter FR, Herbstman JB, et al. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ Health Perspect. 2007;115(11):1670-1676.
10. Fromme H, Mosch C, Morovitz M, et al. Pre- and postnatal exposure to perfluorinated compounds (PFCs). Environ Sci Technol. 2010;44(18):7123-7129.
11. Yahia D, El-Nasser MA, Abedel-Latif M, et al. Effects of perfluorooctanoic acid (PFOA) exposure to pregnant mice on reproduction. J Toxicol Sci. 2010;35(4):527-533.
12. Lau C, Thibodeaux JR, Hanson RG, et al. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci. 2006;90(2):510-518.
13. Lau C, Butenhoff JL, Rogers JM. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol. 2004;198(2):231-241. (Pubitemid 38952836)
14. Maisonet M, McGeehin MA, Christensen KY, et al. Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect. In press.
15. Washino N, Saijo Y, Sasaki S, et al. Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ Health Perspect. 2009;117(4):660-667.
16. Fei C, McLaughlin JK, Tarone RE, et al. Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ Health Perspect. 2007;115(11):1677-1682.
17. Stein CR, Savitz DA, Dougan M. Serum levels of perfluorooctanoic acid and perfluorooctane sulfonate and pregnancy outcome. Am J Epidemiol. 2009;170(7):837-846.
18. Grice MM, Alexander BH, Hoffbeck R, et al. Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med. 2007;49(7):722-729. (Pubitemid 47057651)
19. Nolan LA, Nolan JM, Shofer FS, et al. The relationship between birth weight, gestational age and perfluorooctanoic acid (PFOA)-contaminated public drinking water. Reprod Toxicol. 2009;27(3-4):231-238.
20. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2006;35(5):1146-1150. (Pubitemid 44605528)
21. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. Paediatr Perinat Epidemiol. 2009;23(6):597-608.
22. Whitworth K, Haug LS, Baird DD, et al. Perfluorinated compounds and subfecundity in pregnant women. Epidemiology. 2012;23(2):257-263.
23. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435-439. (Pubitemid 30326123)
24. Blondel B, Morin I, Platt RW, et al. Algorithms for combining menstrual and ultrasound estimates of gestational age: consequences for rates of preterm and postterm birth. BJOG. 2002;109(6):718-720. (Pubitemid 37329287)
25. Skjaerven R, Gjessing HK, Bakketeig LS. Birthweight by gestational age in Norway. Acta Obstet Gynecol Scand. 2000;79(6):440-449. (Pubitemid 30326124)
26. Frömel T, Knepper TP. Biodegradation of fluorinated alkyl substances. Rev Environ Contam Toxicol. 2010;208:161-177. (doi:10.1007/978-1- 4419-6880-7-3).
27. Haug LS, Thomsen C, Becher G. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. J Chromatogr A. 2009;1216(3):385-393.
28. Meltzer HM, Brantsaeter AL, Ydersbond TA, et al. Methodological challenges when monitoring the diet of pregnant women in a large study: experiences from the Norwegian Mother and Child Cohort Study (MoBa). Matern Child Nutr. 2008;4(1):14-27.
29. Richardson DB, Rzehak P, Klenk J, et al. Analyses of case-control data for additional outcomes. Epidemiology. 2007;18(4):441-445. (Pubitemid 46955309)
30. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology. 1995;6(4):450-454.
31. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
32. Hamm MP, Cherry NM, Chan E, et al. Maternal exposure to perfluorinated acids and fetal growth. J Expo Sci Environ Epidemiol. 2010;20(7):589-597.
33. Monroy R, Morrison K, Teo K, et al. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res. 2008;108(1):56-62.
34. Brown MA, Gallery ED. Volume homeostasis in normal pregnancy and pre-eclampsia: physiology and clinical implications. Baillieres Clin Obstet Gynaecol. 1994;8(2):287-310. (Pubitemid 24200809)
35. Hytten F. Blood volume changes in normal pregnancy. Clin Haematol. 1985;14(3):601-612. (Pubitemid 16242421)
36. Andersen ME, Clewell HJ III, Tan YM, et al. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys - probing the determinants of long plasma half-lives. Toxicology. 2006;227(1-2):156-164. (Pubitemid 44404227)
37. Knopp RH, Bergelin RO, Wahl PW, et al. Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes. 1985;34(suppl 2):71-77. (Pubitemid 15044192)
38. Gibson HM. Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth. J Obstet Gynaecol Br Commonw. 1973;80(12):1067-1074.
39. Franceschini N, Savitz DA, Kaufman JS, et al. Maternal urine albumin excretion and pregnancy outcome. Am J Kidney Dis. 2005;45(6):1010-1018. (Pubitemid 40806513)
40. Seong WJ, Chong GO, Hong DG, et al. Clinical significance of serum albumin level in pregnancy-related hypertension. J Obstet Gynaecol Res. 2010;36(6):1165-1173.
41. Gojnic M, Petkovic S, Papic M, et al. Plasma albumin level as an indicator of severity of preeclampsia. Clin Exp Obstet Gynecol. 2004;31(3):209-210. (Pubitemid 39297403)
42. Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA. 2006;295(15):1809-1823.
43. von Ehrenstein OS, Fenton SE, Kato K, et al. Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. Reprod Toxicol. 2009;27(3-4):239- 245.
44. Llorca M, Farré M, Picó Y, et al. Infant exposure of perfluorinated compounds: levels in breast milk and commercial baby food. Environ Int. 2010;36(6):584-592.
45. Brantsaeter AL, Birgisdottir BE, Meltzer HM, et al. Maternal seafood consumption and infant birth weight, length and head circumference in the Norwegian Mother and Child Cohort Study. Br J Nutr. 2012;107(3):436-444.
46. Inoue K, Okada F, Ito R, et al. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect. 2004;112(11):1204-1207. (Pubitemid 39157624)